The established GLP-1 champion versus the triple-agonist challenger. How the next generation of weight loss therapy stacks up against the current standard.
| Feature | Semaglutide | Retatrutide |
|---|---|---|
| Brand Names | Ozempic, Wegovy, Rybelsus | LY3437943 (no brand yet) |
| Mechanism | GLP-1 agonist (single) | GLP-1/GIP/Glucagon (triple) |
| Max Weight Loss | ~15–17% (Phase 3) | ~24% (Phase 2) |
| FDA Status | ✅ Approved | 🔬 Phase 3 |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Dosing | Weekly injection | Weekly injection |
| Available Now? | ✅ Yes — widely prescribed | ❌ Clinical trials only |
Semaglutide activates GLP-1 receptors, which:
This single-pathway approach has proven highly effective, with semaglutide becoming the most prescribed weight loss medication in history.
Retatrutide (LY3437943) activates three hormone receptors simultaneously:
While GLP-1 and GIP reduce food intake, glucagon receptor activation increases energy output. This means retatrutide attacks obesity from both sides: less energy in (appetite suppression) AND more energy out (increased metabolic rate and fat burning). This is theoretically why it shows greater weight loss than single or dual agonists — it's the first approved-track molecule to combine all three pathways.
Semaglutide (STEP 1, Phase 3): 14.9% mean body weight loss at 2.4 mg over 68 weeks. One-third of participants lost ≥20%.
Retatrutide (Phase 2, 48 weeks): Up to 24.2% mean body weight loss at 12 mg dose. Over 90% of participants on the highest dose lost ≥10%, and the weight loss curves had not plateaued at 48 weeks — meaning the final number could be higher with longer treatment.
Key context: Retatrutide's data is from a Phase 2 trial (smaller sample, shorter duration). Phase 3 results (TRIUMPH program) will provide the definitive efficacy data. However, the Phase 2 numbers are unprecedented in the obesity drug field.
Most weight loss drugs show a plateau — the weight loss curve flattens over time as the body adapts. In semaglutide trials, weight loss largely plateaued by week 60. Retatrutide's Phase 2 data showed the weight loss curve still declining at 48 weeks, suggesting the full potential hadn't been reached. If the Phase 3 trial (which runs longer) confirms this, retatrutide could potentially achieve 25–30% weight loss in some patients.
| Milestone | Semaglutide | Retatrutide |
|---|---|---|
| T2D Approval | 2017 (Ozempic) | Not yet — in trials |
| Obesity Approval | 2021 (Wegovy) | Not yet — Phase 3 |
| Phase 3 Program | STEP (completed) | TRIUMPH (ongoing) |
| Est. Availability | Available now | Potentially 2027–2028 |
| Oral Version | Rybelsus (oral tablet) | Unknown — injection only for now |
Even with positive Phase 3 data, FDA review and approval takes time. Retatrutide's TRIUMPH program includes multiple trials for obesity, type 2 diabetes, and NASH/MASH. If all goes well, the earliest possible approval would be late 2026 to mid-2027 — but delays are common in drug development. For patients who need treatment now, semaglutide and tirzepatide are available today.
Based on available data (Phase 3 for semaglutide, Phase 2 for retatrutide):
| Side Effect | Semaglutide | Retatrutide |
|---|---|---|
| Nausea | ~44% | ~25–45% (dose-dependent) |
| Diarrhea | ~30% | ~22–35% |
| Vomiting | ~24% | ~10–20% |
| Heart Rate | Slight increase | Slight increase (glucagon effect) |
| Discontinuation | ~7% due to AEs | ~6% in Phase 2 |
The glucagon component in retatrutide raises theoretical concerns about hyperglycemia, but this was not observed in trials — the GLP-1 and GIP pathways appear to counterbalance glucagon's glucose-raising effects effectively. Phase 3 data will provide a fuller safety picture.
Retatrutide's Phase 2 data is the most impressive ever seen in obesity pharmacotherapy. The ~24% weight loss with curves still declining is genuinely exciting. But it's not available yet, and Phase 2 data doesn't always hold up in Phase 3. Semaglutide is proven, available, and effective right now. For those already on semaglutide or tirzepatide, retatrutide represents a potential future upgrade — not a reason to wait on treatment today. See also our retatrutide deep dive and clinical results page.
In Phase 2 trials, retatrutide showed approximately 24% body weight loss at the highest dose over 48 weeks, compared to semaglutide's approximately 15–17% in Phase 3 trials. Retatrutide is a triple agonist (GLP-1/GIP/glucagon) while semaglutide targets only GLP-1.
As of early 2026, retatrutide is not yet FDA-approved. It is in Phase 3 clinical trials (the TRIUMPH program) conducted by Eli Lilly. If successful, approval could come in late 2026 or 2027.
A triple agonist activates three hormone receptors simultaneously. Retatrutide targets GLP-1 (appetite), GIP (metabolism), and glucagon (energy expenditure). This attacks obesity from multiple angles — reducing intake AND increasing output.
Both share GI side effects (nausea, diarrhea, vomiting) common to GLP-1 agonists. Retatrutide's side effects were manageable with dose titration in Phase 2. Phase 3 data will provide the full safety picture.
Retatrutide is in Phase 3 trials (TRIUMPH program). If successful, Eli Lilly could submit for FDA approval in late 2026, with potential availability in 2027. Semaglutide is available now.
Calculate dosing and check interactions for GLP-1 medications